Stock listing

OTC:VCNX Vaccinex, Inc. Stock

Follow Vaccinex, Inc. into a list and get an email when it puts out news.

Share price · OTC:VCNX

$0.80 USD -0.10 (-11.1%)

Close on Nov 20, 2026

Past year +14.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.80 – $1.01 USDNov 20, 2026
Volume
21 sharesNov 20, 2026
Market cap
$2.14M USDAt the close on Nov 20, 2026 · price × 2.68M shares outstanding
52-week range
$0.31 – $1.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1,147 USDMedian day 300 shares · 9 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Vaccinex, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:VCNX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.80-0.10-11.1%$1.01$1.01$0.8021
$0.90-0.10-10.0%$0.85$0.90$0.78400
$1.000.000.0%$1.02$1.02$1.005,600
$1.000.000.0%$1.00$1.00$1.000
$1.000.000.0%$1.00$1.00$1.00104
$1.000.000.0%$1.00$1.00$1.006
$1.000.000.0%$1.00$1.00$1.001,700
$1.00+0.04+4.2%$1.00$1.00$0.954,700
$0.96-0.03-3.0%$0.96$0.96$0.96100
$0.99-0.01-1.0%$0.91$0.99$0.91600
$1.00+0.08+8.7%$1.00$1.00$0.96800
$0.92+0.02+2.2%$0.92$0.92$0.92100
$0.90+0.19+26.8%$0.90$0.90$0.90300
$0.71+0.01+1.4%$0.70$0.71$0.701,100
$0.70-0.05-6.7%$0.70$0.70$0.70100
$0.750.000.0%$0.75$0.75$0.750
$0.750.000.0%$0.75$0.75$0.752
$0.75-0.07-8.5%$0.70$0.78$0.701,700
$0.820.000.0%$0.82$0.82$0.8251
$0.820.000.0%$0.82$0.82$0.8231
$0.82+0.12+17.1%$0.82$0.82$0.82200
$0.700.000.0%$0.70$0.70$0.702
$0.700.000.0%$0.70$0.70$0.7078
$0.70-0.30-30.0%$0.70$0.70$0.70200
$1.00-0.01-1.0%$1.00$1.00$0.661,200
$1.010.000.0%$1.01$1.01$1.011
$1.01+0.01+1.0%$1.00$1.01$1.00300
$1.00-0.05-4.8%$1.05$1.05$1.001,300
$1.05-0.07-6.3%$1.05$1.05$1.05300
$1.12-0.02-1.8%$1.12$1.12$1.121,100
$1.140.000.0%$1.14$1.14$1.14127
$1.14-0.01-0.9%$1.15$1.15$1.14800
$1.15+0.04+3.6%$1.00$1.15$1.001,800
$1.11+0.10+9.9%$1.01$1.14$1.013,800
$1.010.000.0%$1.01$1.01$1.01500
$1.01-0.02-1.9%$1.01$1.01$1.01100
$1.030.000.0%$1.03$1.03$1.030
$1.030.000.0%$1.03$1.03$1.031
$1.03-0.01-1.0%$1.03$1.03$1.03100
$1.04+0.07+7.2%$1.04$1.04$1.04300
$0.97+0.07+7.8%$0.97$0.97$0.97100
$0.90-0.10-10.0%$0.90$0.90$0.90100
$1.000.000.0%$1.01$1.01$1.00500
$1.000.000.0%$1.00$1.00$1.00500
$1.000.000.0%$1.00$1.00$1.000
$1.000.000.0%$1.00$1.00$1.000
$1.000.000.0%$1.00$1.00$1.00300
$1.000.000.0%$1.00$1.00$1.00800
$1.00-0.06-5.7%$1.05$1.06$1.002,200
$1.06+0.01+1.0%$1.05$1.06$1.051,500
$1.050.000.0%$1.05$1.05$1.050
$1.050.000.0%$1.05$1.05$1.05900
$1.05-0.01-0.9%$1.05$1.05$1.051,500
$1.06+0.31+41.3%$0.75$1.06$0.7510,900
$0.750.000.0%$0.75$0.75$0.750
$0.75-0.25-25.0%$0.75$0.75$0.75500
$1.000.000.0%$1.00$1.00$1.001
$1.000.000.0%$1.00$1.00$1.001,000
$1.000.000.0%$1.00$1.00$1.00300
$1.00+0.28+38.9%$1.00$1.00$0.998,000
$0.720.000.0%$0.72$0.72$0.720
$0.72-0.33-31.4%$0.72$0.72$0.724,000
$1.050.000.0%$1.05$1.05$1.05400
$1.05-0.05-4.5%$1.10$1.10$1.005,100
$1.100.000.0%$1.10$1.10$1.100
$1.10+0.10+10.0%$1.12$1.12$1.106,900

Splits

2 splits since 2023 · OTC:VCNX · every price before a split is adjusted for it

DayRatioWhat
1-for-14Consolidation
1-for-15Consolidation
Ticker
OTC:VCNX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Vaccinex, Inc. news

Vaccinex, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
4 in the last 12 months · 7 in all · newest Oct 7, 2026 · oldest 2025
Decks
4 decks · latest Sep 13, 2022

Valuation

price Nov 20, 2026

Enterprise value
No statements on 6ix yet
P/E
No statements on 6ix yet
EV/sales
No statements on 6ix yet
EV/EBITDA
No statements on 6ix yet
Price/book
No statements on 6ix yet
Gross margin
No statements on 6ix yet
Operating margin
No statements on 6ix yet
Net margin
No statements on 6ix yet
Debt to equity
No statements on 6ix yet
Beta vs S&P 500
1.04

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Vaccinex, Inc. · OTC:VCNXUS$2.14Mn/an/an/an/an/an/an/a1.04
Ernexa Therapeutics Inc. · NASDAQ:ERNAUS$2.30M−US$2.96Mn/an/an/a0.5×n/a0.1×0.86
Cynata Therapeutics Limited · ASX:CYPUS$2.26MUS$1.66Mn/a1.5×n/an/a−540.4%n/an/a
PharmaCyte Biotech, Inc. · NASDAQ:PMCBUS$2.25M−US$15.59Mn/an/an/a0.1×n/a0.0×1.97
Modus Therapeutics Holding AB · OMXSTO:MODTXUS$2.23MUS$1.00Mn/an/an/a2.2×n/a0.0×n/a
Nuformix PLC · LSE:NFXUS$2.22MUS$1.00Mn/an/an/a1.0×n/a0.0×n/a
Medicus Pharma Ltd. · NASDAQ:MDCXUS$2.18M−US$2.73Mn/an/an/an/an/an/a2.03
Senti Biosciences Holdings, Inc. · NASDAQ:SNTIUS$2.06M−US$3.49Mn/a−47.2×n/an/an/an/a2.91
CASI Pharmaceuticals, Inc. · OTC:CASIFUS$2.06MUS$38.79Mn/a1.9×n/an/a−218.6%n/a-0.07
Vectus Biosystems Limited · ASX:VBSUS$2.02MUS$50,9661.9×n/an/a1.3×n/a0.2×n/a
Decoy Therapeutics Inc. · NASDAQ:DCOYUS$1.98M−US$6.19Mn/a−11.6×n/a0.4×n/a0.0×1.28
Median of the othersUS$2.20M−US$1.34M1.9×−5.0×0.8×−379.5%0.0×1.63

Team and board

Officers

OfficerRole
Maurice ZaudererPresident and CEO
Jill SanchezChief Financial Officer
Elizabeth EvansCOO & Senior Vice President, Discovery and Translational Science

Board

DirectorRole
Albert D. FriedbergChairman of the Board
Jacob B. FriebergBoard Member
Maurice ZaudererPresident and CEO

Events

QuarterResultsShare move
Quarter to Mar 31, 2025May 9, 2025 · After close+44.1%
Q3 2024Nov 11, 2024 · Before open+3.9%
Q2 2024Aug 12, 2024 · Before open+4.6%
Q1 2024Apr 2, 2024 · Before open−3.6%
Q3 2023Nov 13, 2023 · Before open−1.1%
Q2 2023Aug 14, 2023 · Before open−7.7%
Q1 2023May 15, 2023 · After close−7.5%
Q4 2022Mar 31, 2023 · After close+5.0%
Q3 2022Nov 14, 2022 · Before open−1.7%
Q2 2022Aug 15, 2022 · After close−2.8%
All 16 quarters
QuarterResultsShare move
Q1 2022May 16, 2022 · Before open−0.8%
Q4 2021Mar 31, 2022 · Before open0.0%
Q3 2021Nov 8, 2021 · Before open−2.0%
Q2 2021Aug 16, 2021 · Before open−4.3%
Q1 2021May 17, 2021 · Before open+2.4%
Q4 2020Mar 31, 2021 · Before open−2.3%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (September 2022)Technical12 slidesSep 13, 2022
Corporate Update (June 2022)Corporate update16 slidesJun 10, 2022
Investor Presentation (March 2019)Investor deck32 slidesMar 18, 2019
Investor Presentation (September 2018)Investor deck30 slidesSep 26, 2018

Open Decks

Financings

RaiseDate
Revenue sharing agreement
Announced: US$60M
Buyers: Pepinemab Development Venture, LP ($60 million funding commitment in exchange for 50% of future economic proceeds from pepinemab neurological indications and 25% from other indications)
Insiders: PDV is an investment entity established by FCMI, an existing Vaccinex investor; Albert Friedberg is Chairman of FCMI and of the Vaccinex Board.
Use of proceeds: Advance development of pepinemab in an enlarged phase 2b clinical trial for Alzheimer's disease
Dec 23, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$12.00 a share on Aug 9, 2018.

Price
US$12.00 a share
Shares offered
3,333,334 shares of common stock
Offering size
US$40 million
Underwriters' option
Up to 500,000 more shares
Underwriters
Oppenheimer & Co., BTIG, Ladenburg Thalmann · In the order on the cover
Shares delivered
On or about Aug 13, 2018

Steps

StepWhen
Draft sent to the SEC in confidenceApr 13, 2018
Filed publiclyJul 9, 2018
Amended twiceNewest Aug 8, 2018
Shares registered with an exchangeAug 8, 2018
Declared effective by the SECAug 9, 2018
Final prospectus, with the priceAug 10, 2018

Open IPO · From the cover of the final prospectus (424B4) filed Aug 10, 2018

Financials

Annual, in USD

Income statement

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue601.0K570.0K275.0K900.0K625.0K523.0K724.0K90.0K
Cost of revenue2.00K199.0K1.03M160.0K
Gross profit623.0K324.0K-309.0K-70.0K
Research and development12.5M16.6M14.0M17.2M21.5M25.7M22.4M16.6M
Operating income-18.7M-22.9M-19.9M-22.5M-28.3M-32.0M-27.3M-21.1M
Depreciation and amortization94.0K119.0K207.0K169.0K307.0K249.0K223.0K206.0K
EBITDA-18.6M-22.8M-19.7M-22.3M-28.0M-31.8M-27.1M-20.9M
Interest expense2.00K1.00K2.00K809.0K489.0K392.0K1.36M
Income before tax-18.6M-20.3M-19.8M-22.4M-28.9M-31.9M-29.5M-18.8M
Income tax000000000
Net income-18.6M-20.3M-19.8M-22.4M-28.9M-31.9M-29.5M-18.7M
Earnings per share, basic-8.88-43.68-98.05-0.78-1.54-2.47-5.65-19.90
Earnings per share, diluted-8.88-43.68-98.05-0.78-1.54-2.47-5.65-19.90

Balance sheet

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents1.11M1.53M6.39M8.59M10.6M2.78M5.62M4.18M1.66M
Short-term investments014.1M
Receivables838.0K961.0K175.0K157.0K898.0K639.0K117.0K
Current assets2.53M3.35M7.48M9.40M11.3M4.01M21.4M4.97M
Property, plant and equipment65.0K136.0K189.0K297.0K416.0K594.0K604.0K601.0K
Total assets2.60M3.63M7.98M9.84M11.7M4.60M22.0M5.58M
Accounts payable3.96M2.04M1.52M1.06M3.17M3.21M2.32M1.91M
Current liabilities5.08M5.92M2.54M2.26M13.2M6.88M6.69M4.17M
Long-term debt026.0K101.0K175.0K1.13M
Total debt25.0K101.0K175.0K249.0K1.13M
Total liabilities5.08M5.94M2.78M2.43M14.3M6.88M6.69M7.35M
Shareholders' equity-2.49M-2.31M5.19M7.41M-26.6M-26.2M-8.62M-125.5M-107.1M
Shares outstanding2.68M892.6K237.5K30.8M22.4M14.9M11.5M1.10M11.5M

Cash flow

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-16.2M-21.4M-19.1M-25.3M-28.6M-30.7M-25.3M-21.4M
Capital spending-22.0K-67.0K-99.0K-32.0K-290.0K-78.0K-235.0K-68.0K
Free cash flow-16.2M-21.4M-19.2M-25.3M-28.9M-30.8M-25.5M-21.5M
Cash from investing-22.0K-67.0K-99.0K-32.0K-290.0K14.1M-14.2M-68.0K
Cash from financing15.8M16.6M17.0M23.3M36.8M13.8M41.0M24.0M
Change in cash-428.0K-4.86M-2.20M-2.01M7.82M-2.84M1.44M2.52M

Open Financials

Filings

FilingDateTypeFiled with
10-K · Annual reportApr 15, 2025Annual reportSEC
NT 10-K · Late filing noticeApr 1, 2025Explanation requestSEC
15-12GMar 27, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 26, 2025Other filingsSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 25, 2025Offer documentSEC
S-8 POSMar 25, 2025Offer documentSEC
S-8 POSMar 25, 2025Offer documentSEC
8-K · Current reportMar 19, 2025Management or board changeSEC
25Mar 17, 2025Other filingsSEC
8-K · Current reportMar 7, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
8-K · Current reportDec 17, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedNov 18, 2024Big-stake noticeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
8-K · Current reportNov 14, 2024Material contractSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
424B3 · ProspectusOct 25, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 25, 2024Other filingsSEC
CORRESP · Letter to the SECOct 22, 2024Other filingsSEC
UPLOAD · Letter from the SECOct 21, 2024Other filingsSEC
S-3 · Registration statementOct 16, 2024Offer documentSEC
8-K · Current reportOct 9, 2024Current reportSEC
DSep 27, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedSep 20, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedSep 20, 2024Big-stake noticeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
8-K · Current reportSep 19, 2024Material contractSEC
8-K · Current reportSep 13, 2024Management or board changeSEC
8-K · Current reportAug 20, 2024Current reportSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 14, 2024Current reportSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedAug 7, 2024Big-stake noticeSEC
4 · Change in ownershipAug 7, 2024Insider tradeSEC
4 · Change in ownershipAug 2, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedAug 1, 2024Big-stake noticeSEC
4 · Change in ownershipAug 1, 2024Insider tradeSEC
8-K · Current reportJul 31, 2024Current reportSEC
424B3 · ProspectusJul 8, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 8, 2024Other filingsSEC
CORRESP · Letter to the SECJul 2, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 1, 2024Other filingsSEC
S-3 · Registration statementJun 27, 2024Offer documentSEC
8-K · Current reportJun 6, 2024Current reportSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
10-Q · Quarterly reportMay 15, 2024Quarterly reportSEC
4/A · Change in ownership, amendedMay 14, 2024Insider tradeSEC
4/A · Change in ownership, amendedMay 14, 2024Insider tradeSEC
4/A · Change in ownership, amendedMay 14, 2024Insider tradeSEC
4/A · Change in ownership, amendedMay 14, 2024Insider tradeSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveMay 13, 2024Other filingsSEC
S-8 · Registration statement for employee plansMay 10, 2024Offer documentSEC
424B3 · ProspectusMay 9, 2024Offer documentSEC
8-K · Current reportMay 9, 2024Meeting outcomeSEC
S-3/A · Registration statement, amendedMay 8, 2024Offer documentSEC
CORRESP · Letter to the SECMay 2, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 2, 2024Other filingsSEC
S-3 · Registration statementApr 26, 2024Offer documentSEC
10-K/A · Annual report, amendedApr 25, 2024Annual reportSEC
4 · Change in ownershipApr 22, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 17, 2024Other filingsSEC
424B3 · ProspectusApr 16, 2024Offer documentSEC
CORRESP · Letter to the SECApr 12, 2024Other filingsSEC
DApr 12, 2024Other filingsSEC
DApr 12, 2024Other filingsSEC
8-K · Current reportApr 12, 2024Current reportSEC
DApr 12, 2024Other filingsSEC
UPLOAD · Letter from the SECApr 3, 2024Other filingsSEC
ARS · Annual report to shareholdersApr 2, 2024Annual reportSEC
DEF 14A · Proxy statementApr 2, 2024Meeting noticeSEC
S-3 · Registration statementApr 2, 2024Offer documentSEC
4 · Change in ownershipApr 1, 2024Insider tradeSEC
4 · Change in ownershipApr 1, 2024Insider tradeSEC
10-K · Annual reportApr 1, 2024Annual reportSEC
NT 10-K · Late filing noticeApr 1, 2024Explanation requestSEC
8-K · Current reportApr 1, 2024Material contractSEC
8-K · Current reportMar 28, 2024Current reportSEC
424B5 · ProspectusMar 28, 2024Offer documentSEC
8-K · Current reportMar 27, 2024Current reportSEC
4 · Change in ownershipMar 22, 2024Insider tradeSEC
4 · Change in ownershipMar 22, 2024Insider tradeSEC
4 · Change in ownershipMar 22, 2024Insider tradeSEC
4 · Change in ownershipMar 22, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 14, 2024Insider tradeSEC
8-K · Current reportMar 4, 2024Management or board changeSEC
8-K · Current reportFeb 21, 2024Current reportSEC
8-K · Current reportFeb 15, 2024Current reportSEC
8-K · Current reportFeb 13, 2024Meeting outcomeSEC
SC 13D/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedFeb 12, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
SC 13G · Big-stake noticeFeb 9, 2024Big-stake noticeSEC
8-K/A · Current report, amendedFeb 8, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
8-K · Current reportFeb 7, 2024Material contractSEC
EFFECT · Notice that a registration is effectiveJan 22, 2024Other filingsSEC
424B3 · ProspectusJan 19, 2024Offer documentSEC
CORRESP · Letter to the SECJan 17, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 16, 2024Other filingsSEC
S-3 · Registration statementJan 10, 2024Offer documentSEC
DEF 14A · Proxy statementJan 8, 2024Meeting noticeSEC
4 · Change in ownershipDec 28, 2023Insider tradeSEC
PRE 14A · Preliminary proxy statementDec 28, 2023Meeting noticeSEC
4 · Change in ownershipDec 12, 2023Insider tradeSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
4 · Change in ownershipNov 3, 2023Insider tradeSEC
8-K · Current reportOct 26, 2023Current reportSEC
4 · Change in ownershipOct 25, 2023Insider tradeSEC
SC 13D/A · Big-stake notice, amendedOct 18, 2023Big-stake noticeSEC
8-K · Current reportOct 13, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedOct 12, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeOct 11, 2023Big-stake noticeSEC
4 · Change in ownershipOct 5, 2023Insider tradeSEC
4 · Change in ownershipOct 5, 2023Insider tradeSEC
4 · Change in ownershipOct 5, 2023Insider tradeSEC
8-K · Current reportOct 4, 2023Material contractSEC
424B4 · ProspectusOct 2, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 29, 2023Other filingsSEC
S-1MEF · Registration of more shares for the same offeringSep 28, 2023Offer documentSEC
8-K · Current reportSep 27, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedSep 26, 2023Big-stake noticeSEC
CORRESP · Letter to the SECSep 26, 2023Other filingsSEC
CORRESP · Letter to the SECSep 26, 2023Other filingsSEC
8-K · Current reportSep 26, 2023Current reportSEC
S-1/A · Registration statement, amendedSep 26, 2023Offer documentSEC
4 · Change in ownershipSep 25, 2023Insider tradeSEC
8-K · Current reportSep 22, 2023Current reportSEC
8-K · Current reportSep 22, 2023Material contractSEC
UPLOAD · Letter from the SECSep 20, 2023Other filingsSEC
S-1 · Registration statementSep 14, 2023Offer documentSEC
8-K · Current reportSep 13, 2023Meeting outcomeSEC
8-K · Current reportAug 22, 2023Material contractSEC
DEF 14A · Proxy statementAug 14, 2023Meeting noticeSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
PRE 14A · Preliminary proxy statementAug 4, 2023Meeting noticeSEC
424B3 · ProspectusJul 11, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 11, 2023Other filingsSEC
CORRESP · Letter to the SECJul 7, 2023Other filingsSEC
UPLOAD · Letter from the SECJun 20, 2023Other filingsSEC
S-3 · Registration statementJun 14, 2023Offer documentSEC
8-K · Current reportMay 30, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedMay 25, 2023Big-stake noticeSEC
8-K · Current reportMay 19, 2023Current reportSEC
424B5 · ProspectusMay 19, 2023Offer documentSEC
4 · Change in ownershipMay 16, 2023Insider tradeSEC
8-K · Current reportMay 15, 2023Material contractSEC
4 · Change in ownershipMay 15, 2023Insider tradeSEC
4 · Change in ownershipMay 15, 2023Insider tradeSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
4 · Change in ownershipMay 15, 2023Insider tradeSEC
4 · Change in ownershipMay 15, 2023Insider tradeSEC
4 · Change in ownershipMay 15, 2023Insider tradeSEC
8-K · Current reportMay 12, 2023Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveApr 13, 2023Other filingsSEC
CORRESP · Letter to the SECApr 10, 2023Other filingsSEC
UPLOAD · Letter from the SECApr 7, 2023Other filingsSEC
ARS · Annual report to shareholdersApr 6, 2023Annual reportSEC
DEF 14A · Proxy statementApr 6, 2023Meeting noticeSEC
SC 13D/A · Big-stake notice, amendedApr 5, 2023Big-stake noticeSEC
4 · Change in ownershipApr 3, 2023Insider tradeSEC
4 · Change in ownershipApr 3, 2023Insider tradeSEC
4 · Change in ownershipApr 3, 2023Insider tradeSEC
4 · Change in ownershipApr 3, 2023Insider tradeSEC

This page holds 200 of 475 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Vaccinex, Inc.’s releases · as of Dec 31, 2025

Common shares
2,676,637
Fully diluted
2,676,637

Fully diluted

LineSharesAs of
Common shares2,676,637Dec 31, 2025

Share count over time

CountShares
Nov 22, 20262,676,637
Dec 31, 20252,098,900

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Alan L Crane
Other companies: Pandion Therapeutics Inc (Director · Jul 16, 2020 – Apr 1, 2021 · Past); T2 Biosystems, Inc. (Director · Aug 6, 2014 – Aug 12, 2014 · Past); Ocular Therapeutix, Inc. (Director · Jul 24, 2014 – Jul 24, 2014 · Past); Dare Bioscience, Inc. (Director · Apr 10, 2014 – Jun 22, 2016 · Past); Sirtris Pharmaceuticals Inc (Director · May 22, 2007 – May 22, 2007 · Past); Momenta Pharmaceuticals Inc (Director · Dec 30, 2005 – Jun 11, 2009 · Past)
Director · Aug 9, 2018 – Aug 9, 2018 · Past
Barbara Yanni
Other companies: Trevena, Inc. (Chair of Compensation Committee · Since at least Jul 1, 2014); Oncorus Inc (Director · Jul 27, 2021 – Jun 23, 2022 · Past); Akcea Therapeutics Inc (Director · Dec 13, 2019 – Oct 12, 2020 · Past)
Director · Aug 9, 2018 – May 10, 2024 · Past
Jeff Goater
Other companies: LogicBio Therapeutics Inc (Director · Dec 10, 2020 – Nov 16, 2022 · Past); Surface Oncology Inc (Director · Apr 18, 2018 – Sep 8, 2023 · Past)
Director · Aug 9, 2018 – May 11, 2021 · Past
Bala S Manian
Other companies: Equillium, Inc. (Director · Oct 11, 2018 – May 21, 2025 · Past)
Director · Aug 9, 2018 – May 10, 2024 · Past
Albert D. FriedbergChairman of the Board · Since at least Aug 9, 2018
Alejandro M BerlinDirector · Aug 9, 2018 – May 15, 2019 · Past
Chrystyna Bedrij StecykDirector · May 14, 2020 – May 10, 2024 · Past
Elizabeth EvansCOO & Senior Vice President, Discovery and Translational Science · Since at least May 11, 2021
Ernest S SmithSVP, Research & CSO · Aug 9, 2018 – Mar 21, 2024 · Past
Gerald E Van StrydonckDirector · Aug 9, 2018 – May 10, 2024 · Past
All 17 people
PersonSeat
Jacob B. FriebergBoard Member · Since at least Aug 9, 2018
Jill SanchezChief Financial Officer · Since at least Mar 14, 2024
John E LeonardSVP, Development · Aug 9, 2018 – Mar 31, 2023 · Past
Maurice ZaudererPresident and CEO · Since at least Aug 9, 2018
Raymond E WatkinsSVP & Chief Operating Officer · Aug 9, 2018 – Feb 25, 2020 · Past
Robert ScalaChief Commercial Officer · Sep 1, 2020 – Sep 1, 2020 · Past
Scott E RoyerChief Financial Officer · Aug 9, 2018 – Mar 31, 2023 · Past

Open People

Log in to ask 6ix AI your own questions about Vaccinex, Inc.